A popular class of weight loss drugs may offer more lasting success than assumed, new data from Epic Research suggests. The study of medical records found that a slight majority of people who took GLP-1 drugs like semaglutide either maintained or improved their weight loss in the year after they stopped using the…
A popular class of weight loss and diabetes drugs looks to be safer than feared, at least so far. This week, the Food and Drug Administration announced it hasn’t found compelling evidence that Wegovy, Ozempic, and other GLP-1 drugs can cause suicidal thoughts or behaviors—a concern that first emerged last year. The…
